GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
GRAIL, Inc.NASDAQ: GRAL
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $19.56M rose 38.0% year over year, ahead of the -90.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at -8.4% a year.
Context
- Stock-based compensation amounted to 39.6% of revenue in FY2025, down 28.9 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +38.0% holds above the trailing-twelve-month pace of -90.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 58.28M USD
- Year-over-year change
- -32.3%
- 4-year CAGR
- -45.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.28M | -32.3% |
| FY2024 | 2024-12-31 | 86.08M | -11.5% |
| FY2023 | 2023-12-31 | 97.24M | +28.4% |
| FY2022 | 2022-12-31 | 75.73M | -88.9% |
| FY2021 | 2021-12-31 | 681.91M | — |
Stock-Based Compensation vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's LTM Jun 2026 stock-based compensation of $5.97M is the smallest of the 10 companies compared; the peer median is $32.2M.
- Its year-over-year change of -90.3% is the lowest of 9, against a peer median of -6.7%.
- Stock-based compensation amounts to 3.6% of revenue for GRAL, versus a peer median of 9.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381.42M | +21.6% | +32.5% | 14.1% | |
| LTM Sep 2026 | $210.96M | +32.4% | +20.6% | 16.5% | |
| LTM Mar 2026 | $44.49M | -8.9% | +8.1% | 13.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $35.7M | +95.3% | -8.5% | 7.9% |
| LTM Mar 2026 | $32.2M | -31.9% | -2.6% | 3.9% | |
| LTM Mar 2026 | $29.03M | -33.3% | +6.6% | 9.1% | |
| LTM Jun 2026 | $28.16M | -29.2% | +18.8% | 3.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $25.54M | — | — | 6.4% |
| LTM Mar 2026 | $9.76M | -4.5% | -21.4% | 15.1% | |
| LTM Jun 2026 | $5.97M | -90.3% | -8.4% | 3.6% | |
| Peer median (excluding GRAL) | $32.2M | -6.7% | +7.4% | 9.1% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.25B) | (5.4B) | (1.47B) | (2.03B) | (408.35M) |
| Depreciation & Amortization | 58.45M | 154.76M | 158.7M | 158.06M | 156.34M |
| Deferred Income Tax | 0 | (39.06M) | (38.15M) | (134.25M) | (126.15M) |
| Stock-Based Compensation | 681.91M | 75.73M | 97.24M | 86.08M | 58.28M |
| Change in Working Capital | 21.59M | (14.46M) | 7.72M | (24.28M) | 12.41M |
| Accounts Receivables | (6.88M) | (8.68M) | (1.38M) | (3.37M) | 1.69M |
| Inventory | (5.67M) | (14.08M) | (1.94M) | 3.07M | 2.62M |
| Accounts Payables | 1.3M | 2.34M | 2.89M | (14.64M) | (2.73M) |
| Other Working Capital | 32.85M | 5.95M | 8.16M | (9.35M) | 10.84M |
| Other Non-Cash Items | (201M) | 4.66B | 644.39M | 1.36B | 8.46M |
| Operating Cash Flow | (688.13M) | (561.31M) | (595.8M) | (577.16M) | (299.01M) |
| Capital Expenditures | (69.93M) | (22.86M) | (12.89M) | (5.21M) | (909K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (545.8M) | (1.31B) |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.22B |
| Other Investing Activities | 414.74M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 344.81M | (22.86M) | (12.89M) | (551.01M) | (85.05M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.98M | 0 | 0 | 0 | 423.32M |
| Common Stock Repurchased | (170K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 388.93M | 604.82M | 463.77M | 1.24B | 0 |
| Financing Cash Flow | 394.74M | 604.82M | 463.77M | 1.24B | 423.32M |
| Effect of Forex Changes | (194.61M) | (511K) | 305K | (62K) | (147K) |
| Net Change in Cash | (143.19M) | 20.13M | (144.62M) | 116.07M | 39.12M |
| Free Cash Flow | (758.06M) | (584.17M) | (608.69M) | (582.36M) | (299.01M) |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.